RPMI-8226/iRFP stable cell line

RPMI-8226/iRFP cells are derived from the human myeloma RPMI-8226 cell line by stably integration of a constitutive miRFP670 stably expression construct. The RPMI-8226 cell line is a valuable tool for understanding multiple myeloma and developing new treatments, including CAR-T (chimeric antigen receptor T-cell) therapy. RPMI-8226/iRFP cells stably express miRFP670, can be used for in vitro assays and in vivo imaging.